This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.

开始日期2024-11-21

申办/合作机构

Idorsia Pharmaceuticals Ltd.

[+1]

NCT06630390

/ Completed临床2期IIT

Randomized, Double-blind Trial of Daridorexant to Prevent Delirium After Heart Surgery

The goal of this phase 2 clinical trial is to demonstrate the feasibility of the current study methods and obtain preliminary data for an adequately powered trial of daridorexant with the aim of preventing delirium after heart surgery. The main aims this feasibility trial aims to answer are to demonstrate: (1) the feasibility of study recruitment; (2) the ability deliver study compounds to subjects according to the proposed methods; and (3) completeness of data capture; and (4) recording of potential adverse events.
Participants will: (1) complete a baseline visit; (2) take the study drug--either daridorexant or placebo--each of the first 3 nights after heart surgery; and (3) be evaluated for sleep and delirium each of the first three days after heart surgery.

开始日期2024-11-11

申办/合作机构

University of Rochester

NCT06311864

/ Enrolling by invitationN/A

Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada

The purpose of this observational study is to evaluate the impact of daridorexant on quality of life, work productivity and insomnia symptoms in Canadian adults suffering from insomnia.

开始日期2024-06-20

申办/合作机构

Peripharm, Inc.

[+1]

100 项与盐酸达利雷生相关的临床结果

登录后查看更多信息

100 项与盐酸达利雷生相关的转化医学

登录后查看更多信息

100 项与盐酸达利雷生相关的专利（医药）

登录后查看更多信息

126

项与盐酸达利雷生相关的文献（医药）

2025-07-01·SLEEP MEDICINE

Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the transition from night to day in insomnia disorder

Article

作者: Luyet, Pierre-Philippe ; Dauvilliers, Yves ; Olivieri, Antonio ; Braunstein, Guy ; Zammit, Gary

OBJECTIVE/BACKGROUND:

Reducing wakefulness throughout the night without next-day residual effects are essential characteristics for drugs for chronic insomnia disorder. In Phase 3 trials, daridorexant significantly reduced polysomnography-determined wake after sleep onset (WASO) versus placebo, and rates of daytime somnolence were similar to placebo. This analysis examines the effect of daridorexant on WASO in each 2-h quarter (Q) of the night (8-h recording), and on next-morning sleepiness, daytime alertness and ability to function (assessed daily using visual analog scales [VAS]), and the correlation between these night and day assessments.

PATIENTS/METHODS:

Data from 930 patients with insomnia disorder randomized to daridorexant 50 mg (n = 310), 25 mg (n = 310) or placebo (n = 310) for 3 months were analyzed.

RESULTS:

At Month 1, daridorexant 25 mg and 50 mg significantly decreased WASO versus placebo in Q2 (least-square mean difference [LSMD] 25 mg: -4.7 min p < 0.0001; 50 mg: -7.1 min p < 0.0001), Q3 (LSMD 25 mg: -3.3 min p = 0.0086; 50 mg: -7.2 min p < 0.0001) and Q4 (LSMD 25 mg: -4.3 min p = 0.0055; 50 mg -8.5 min p < 0.0001). Results were similar at Month 3. VAS scores for next-morning sleepiness, daytime alertness and ability to function improved from Day 1 in all groups and continued to improve over time, with treatment numerically ranked as daridorexant 50 mg > 25 mg > placebo. No significant correlations were found between WASO (overall and at any quarter) and the three VAS scores.

CONCLUSION:

Daridorexant reduces wakefulness throughout the entire night while independently decreasing morning sleepiness and improving daytime functioning and alertness.

2025-06-03·Expert Opinion On Drug Safety

Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)

Article

作者: Rosenblat, Joshua D ; Mansur, Rodrigo B ; Kwan, Angela T H ; Ho, Roger ; McIntyre, Roger S ; Rhee, Taeho Greg ; Teopiz, Kayla M ; Cao, Bing ; Le, Gia Han ; Wong, Sabrina

BACKGROUND:

Package inserts for the FDA-approved dual orexin receptor antagonists (DORAs) suvorexant, lemborexant and daridorexant state that suicide risk should be monitored. It remains unknown whether suicidality is attributed to DORAs. We aim to evaluate suicidality associated with DORAs reported to the FDA Adverse Event Reporting System (FAERS).

METHODS:

The reporting odds ratio (ROR) was determined with trazodone as the control. Significant disproportionate reporting was determined when 95% confidence intervals (CIs) did not encompass 1.0. We used information components (ICs) to calculate the lower limit of the 95% CI (IC₀₂₅). IC was significantly increased when the IC₀₂₅ ≥0.

RESULTS:

Suvorexant (0.025 ROR), lemborexant (0.019 ROR) and daridorexant (0.002 ROR) were significantly associated with lower odds of reported completed suicides compared to trazodone (p < 0.05). There was no significantly increased RORs for the DORAs regarding suicidal ideation, depression suicidal, suicidal behavior and suicide attempts. Nonsignificant associations between all parameters of suicidality were observed for each DORA using IC₀₂₅.

CONCLUSION:

We did not find a significant association between any parameter of suicidality captured in the FAERS for each DORA. All persons treated for insomnia pharmacologically/non-pharmacologically should be evaluated for emergence/worsening of any suicidality aspect.

2025-05-01·ALCOHOL

Effects of daridorexant on rest/wake activity patterns and drinking in adult rats exposed to chronic ethanol vapor in adolescence

Article

作者: Amodeo, L R ; Ehlers, C L ; Benedict, J ; Wills, D N

Disturbance in sleep and activity rhythms are significant health risks associated with alcohol use during adolescence. Many investigators support the theory of a reciprocal relationship between disrupted circadian rhythms, sleep patterns, and alcohol usage. However, in human studies it is difficult to disentangle other factors (i.e. lifestyle, psychiatric, genetic) when determining what is causal in the relationship between substance use and sleep/activity disruptions. To this end, we used an animal model of adolescent alcohol exposure whereby male and female Wistar rats are exposed to 5 weeks of intermittent alcohol vapor during adolescence (P22-P57). Five days after ethanol vapor rats were allowed to select to drink alcohol or water in a two-bottle choice procedure for a period of 5 h, 4 days a week for 6 weeks. Activity data was collected using a "Fitbit-like" device during vapor exposure, during acute withdrawal, and after 3 weeks of protracted withdrawal. Significant changes in rest/wake activity and circadian measures were seen during 24-h withdrawal and after 3 weeks of withdrawal. Four weeks following withdrawal, the effects of the dual orexin antagonist, Daridorexant, (DAX 30 mg, 100 mg, or vehicle control), on alcohol drinking and rest and activity rhythms were assessed over a 24 h period. Both daridorexant doses led to changes in circadian measures and rest/wake activity patterns. These results showed that daridorexant reduced activity, but it did not improve rest quality as measured by the mean inactive episode duration and inactive fragmentation ratio. Additionally, we did not find a significant difference in drinking behavior in animals treated with the orexin antagonist. Thus, it appears that data from this animal model do not support the use of this drug to improve adolescent alcohol-induced sleep disturbance and/or to decrease alcohol drinking.

171

项与盐酸达利雷生相关的新闻（医药）

2025-05-28

·汇聚南药

被围剿的日本新药！

昨日，卫材宣布卫材原研的双食欲素受体拮抗剂——莱博雷生（中文商品名：达卫可®）正式获批上市，用于治疗成人失眠，特别是入睡困难和/或睡眠维持困难。2019年12月20日，莱博雷生率先在美国上市，后续在全球20多个国家及地区获得药品批准和上市。值得注意的是，2021年6月，莱博雷生就已在中国香港上市，得益于“港澳药械通”政策，2023年1月广州就已开出首张该品处方。莱博雷生已完成了部分患者教育，对国内医生患者来说并不算陌生。四代助眠药失眠已经成了现代人的一大困扰。据《2024中国居民睡眠健康白皮书》显示：2024年，64%的居民正在面临睡眠质量欠佳的困扰，59%的人存在失眠症状，完全无睡眠障碍的人群仅占19%。目前助眠药物已发展出四代，研发向着疗效更佳，副作用更小的方向前进着。第一代药物（巴比妥类）：以苯巴比妥为代表，成瘾性强、疗效局限；第二代药物（苯二氮卓类）：地西泮、艾司唑仑等，安全性显著提升，但长期用药仍伴随反跳性失眠、记忆损伤等风险，临床需严格监测；第三代药物（非苯二氮卓类）：唑吡坦、佐匹克隆等，可显著减少次日宿醉效应，是目前失眠治疗金标准；第四代药物（双重食欲素受体拮抗剂类）：苏沃雷生、达利雷生等，精准调控睡眠-觉醒周期，昼夜节律紊乱患者新希望。卫材的莱博雷生同样属于第四代助眠药物，也是目前国内唯一一款上市的第四代助眠药物。而除此之外，这个产品最大的产品优势其实在于：无成瘾性，不会出现戒断症状。无成瘾性助眠药市场？国内有睡眠障碍问题的人群占比非常高，但是助眠药物的市场并没有很大，据不完全统计统计，国内前三代助眠药物合计销售额还停留在10亿左右。市场不佳最主要原因还是成瘾性问题，前三代药物，包括第四代的苏沃雷生，均存在身体依赖性问题，停药会产生戒断反应，因此这些助眠药在国内均被纳入第二类精神药品目录，受强监管。而莱博雷生则暂未发现成瘾性，据卫材公布的临床数据显示，患者服用莱博雷生后，其记忆和认知功能影响小，患者醒来后对开展工作及其他日间活动，尤其是驾驶影响小，大部分患者长期（12个月）使用后停药，不会出现戒断症状，也不会出现失眠反弹，上市后至今没有发现具有成瘾性。莱博雷生凭借暂未发现成瘾性的卖点，已成为日本失眠治疗的一线推荐药物。日本市场数据显示，其市场份额在上市三年内反超传统药物，患者依从性高达78%。因其成瘾性低，目前美国和日本对莱博雷生的监管等级都不高。国内对于莱博雷生的监管尚不明确，但应当会参照美日政策进行考量。那么若莱博雷生未被列入精神药物管控目录，该品种的未来将不可限量。被围剿的日本新药日本研发的药物，总是更受国内仿制药企业关注，中日两国种族差异小，仿制药大部分只需要进行一个桥接试验即可，需要进行大临床的可能性非常小。由此可以发现，但凡日本有新药在国内上市，就必定有国内企业争相仿制。2024年6月，大冢制药的布瑞哌唑片在国内获批上市，不到一年，国内仿制申请就已达三十多家。2024年7月，协和麒麟的依伏卡塞片在国内获批上市，两个月后，就有三家企业提交了上市申请。2025年4月，日本兴和制药的佩玛贝特片在国内获批上市，一个月后，提交仿制申请企业已达5家。莱博雷生片，也免不了被国内仿制企业瞄准，莱博雷生化合物专利预计2031年06月12日到期，组合物专利预计2035年10月21日到期。离产品专利到期还有五六年，国内已有企业登记了BE试验。外资原研企业在国内上市所花费了大量的时间和金钱，上市后窗口期仅有短短几年，目前莱博雷生片的专利保护期还有五六年，尚有竞争余地。助眠类药物市场广阔，但品种的患者教育还是较为困难的，国内竞争环境特殊，也有在国外大杀四方的药物进国内后水土不服的情况，就看卫材如何布局了。喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~免责声明“汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：药通社往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

上市批准

2025-05-28

·GlobeNewswire-Health Care

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025

Allschwil, Switzerland – May 28, 2025At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors. The meeting was attended by 166 shareholders, representing a total of 97’748’740 shares, or 43.28% of the total outstanding shares. Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update. Jean-Paul Clozel, MD, Chairman of the Board of Directors, commented:“On behalf of the Board, I would like to thank the shareholders for their support and loyalty. I strongly believe that with their backing, with our products and pipeline, and with our people working to ramp-up the sales of QUVIVIQ and activate the pipeline, Idorsia can become one of the most successful biotech companies in Europe.” The shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024. Shareholders also endorsed the Compensation Report 2024 and the Sustainability Report 2024 by way of consultative vote. The shareholders approved the appropriation of available earnings and that the net loss for the year 2024 be carried forward. The shareholders granted discharge to all members of the Board of Directors and of the Executive Committee for the financial year 2024. The shareholders approved the amendments to the Articles of Association regarding share capital. The shareholders re-elected all Board members who stood for re-election for a term of office until the conclusion of the AGM 2026. In addition, the shareholders elected Jean-Paul Clozel as Chairman of the Board, and the members of the Nominating, Governance and Compensation Committee: Srishti Gupta, Mathieu Simon, and Bart Filius. Following the AGM, the Board of Directors of Idorsia comprises a total of 5 members: Jean-Paul Clozel (Chairman), Mathieu Simon, Srishti Gupta, Sandy Mahatme, and Bart Filius. Shareholders approved the aggregate maximum amount of compensation for the Board of Directors for the term of office until the AGM 2026 and aggregate maximum amount of compensation for the Idorsia Executive Committee (IEC) for the financial year 2026. BachmannPartner AG, who was represented by Mr Alain Bachmann, was re-elected as Independent Proxy for a term of office until the conclusion of the AGM 2026. Deloitte AG, Basel, was re-elected as the company's statutory auditors for the financial year 2025 (for a term of office until the conclusion of the AGM 2026). Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contactInvestor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

高管变更

2025-05-27

·药事纵横

国内首款！卫材药业失眠新药莱博雷生获批上市

5月27日，卫材药业宣布旗下双重食欲素受体拮抗剂莱博雷生片（商品名：达卫可®/达卫眠）正式获得中国国家药品监督管理局（NMPA）批准上市，这是国内首款获批的OX1R/OX2R拮抗剂，为饱受失眠困扰的患者带来了喜讯。失眠治疗长期以来依赖苯二氮卓类和非苯二氮卓类药物，这些药物通过增强γ-氨基丁酸（GABA）的抑制作用，强制“关闭”觉醒系统。但是，这类药物常伴随次日嗜睡、认知功能下降、依赖性和戒断反应等问题，甚至可能扰乱睡眠结构，长期使用后患者往往面临“药越吃越多，效果越来越差”的困境。莱博雷生则通过竞争性结合食欲素受体OX1R和OX2R（尤其对OX2R亲和力更强），精准抑制促进觉醒的神经肽信号，从源头调节睡眠-觉醒节律，而非简单压制中枢神经系统。这种机制不仅缩短了入睡时间、减少夜间觉醒次数，还能同时延长非快速眼动期（NREM）和快速眼动期（REM），使睡眠结构更接近生理状态。临床数据显示，患者服用后总睡眠时间平均增加60-90分钟，且次日认知功能、驾驶能力几乎不受影响，这对需要高度专注的职业人群尤为重要。传统安眠药最受诟病的依赖性问题，在莱博雷生身上得到显著改善。两项关键III期临床试验（SUNRISE 1和SUNRISE 2）表明，患者连续用药12个月后突然停药，未出现反跳性失眠或戒断症状，且睡眠改善效果在停药后仍能维持两周以上。这一特性使其成为长期失眠患者的更优选择，尤其是老年人群，传统药物导致的跌倒风险在莱博雷生治疗中显著降低。安全性数据进一步显示，莱博雷生的不良反应以轻中度为主，最常见为嗜睡（发生率约5%），而复杂的睡眠行为、呼吸抑制等严重副作用发生率极低。其代谢不依赖肝酶CYP3A4，与多种药物相互作用风险较小，为合并慢性病的患者提供了更高的用药自由度。莱博雷生自2019年在美国获批以来，它已在全球20余个国家和地区上市，并成为日本失眠治疗的一线推荐药物。日本市场数据显示，其市场份额在上市三年内反超传统药物，患者依从性高达78%。在中国，该药通过“港澳药械通”政策率先于大湾区试点使用，为此次全国获批铺平道路。尽管莱博雷生在国内具有“首款双食欲素拮抗剂”的先发优势，但市场竞争已悄然升温。全球范围内，同类药物如苏沃雷生（Suvorexant）和达利多雷生（Daridorexant）已在部分国家上市。先声药业于2024年7月提交了盐酸达利雷生片的上市申请，该药物同样靶向OX1R/OX2R受体，且在欧洲获批时强调其改善日间功能的优势。此外，扬子江药业的YZJ-1139已完成II期临床，数据显示其快速起效和低残留效应特点，未来可能成为莱博雷生的有力竞争者。中国市场的独特需求也推动了莱博雷生的本土化适应。根据《中国成人失眠诊断与治疗指南（2023版）》，该药被列为IA级推荐，尤其适用于对传统药物不耐受或存在依赖风险的患者。卫材中国总裁冯艳辉透露，公司已同步启动患者援助计划，并与互联网医疗平台合作，构建从处方到配送的闭环服务，缓解基层医疗资源不足的痛点。对国内药企而言，这一领域既是机遇也是挑战。尽管莱博雷生目前独占鳌头，但国产同类药物，如YZJ-1139已进入III期临床，未来或凭借价格优势和政策支持抢占市场。与此同时，医生教育、患者认知提升仍是普及新疗法的关键，许多患者仍将“助眠”等同于“镇静”，如何传递“调眠”理念，需要行业、学界与媒体的共同推动。尽管莱博雷生的临床数据亮眼，但如何定义“长期安全”仍需要审慎考虑。一是特殊人群数据不足**：现有研究主要针对普通成年人和老年人，但对孕妇、肝肾功能不全患者的证据有限；二是成本与可及性：作为原研药，莱博雷生的定价可能高于传统药物，如何通过医保谈判或患者援助计划提升可及性，将是其市场渗透的关键。当然还有需要笔者未考虑到的方面值得进一步探讨研究。总之，未来，随着更多创新疗法的涌现和精准医疗的深化，失眠或许将不再是一个令人绝望的“不眠之夜”，而成为可被科学管理的健康议题。信息来源：[1] 卫材官网. From https://www.eisai.com/innovation/research/pipeline/index.html[2] 卫材Dayvigo®（莱博雷生片）相关资料已成功纳入粤港澳大湾区内地临床急需进口港澳药品医疗器械预审品种数据库. Retrieved Sep 3，2022, from https://mp.weixin.qq.com/s/uO3XpHXYGAE_ynWWBvhMmA药事纵横投稿须知：稿费已上调，欢迎投稿

上市批准临床3期临床结果

100 项与盐酸达利雷生相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11886 D11887	盐酸达利雷生	-	DB15031

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
入睡和睡眠障碍	美国	Idorsia Pharmaceuticals Ltd.	2022-01-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
睡眠	申请上市	中国	江苏先声药业有限公司	2024-07-16
睡眠	申请上市	中国	Farmea	2024-07-16
睡眠	申请上市	中国	Idorsia Pharmaceuticals Deutschland GmbH	2024-07-16
创伤后应激障碍	临床2期	美国	Idorsia Pharmaceuticals Ltd.	2023-11-02
阻塞性睡眠呼吸暂停综合征	临床1期	德国	Idorsia Pharmaceuticals Ltd.	2019-03-14
慢性阻塞性肺疾病	临床1期	德国	Idorsia Pharmaceuticals Ltd.	2018-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05597020 (CTgov)	临床4期	入睡和睡眠障碍 \| 夜尿	60	Placebo	構獵鬱願積網鑰鹹夢顧(窪簾艱艱觸廠積鬱憲窪) = 膚膚繭餘餘簾艱簾憲壓糧網齋廠壓夢遞鹽窪製 (鹹壓鏇鏇餘獵獵鑰構壓, 艱醖艱鑰鏇窪鹽鬱齋廠 ~ 構選積鹽顧艱遞網獵窪) 更多	-	2025-04-18
NCT05702177 (Pubmed \| J Psychopharmacol)	临床1期	-	36	Daridorexant 25 mg	淵廠壓憲憲襯蓋網鏇鑰(築鑰餘夢糧憲夢壓積廠) = 齋築夢糧膚廠憲鏇窪選餘齋築觸鑰觸膚遞鏇鏇 (壓艱鏇鬱築鏇選膚顧齋 ) 更多	积极	2024-12-06
				Daridorexant 50 mg	淵廠壓憲憲襯蓋網鏇鑰(築鑰餘夢糧憲夢壓積廠) = 糧鏇觸艱鑰構築糧糧鹽餘齋築觸鑰觸膚遞鏇鏇 (壓艱鏇鬱築鏇選膚顧齋 ) 更多
EAN2024	N/A	入睡和睡眠障碍	23	Daridorexant	範襯餘窪製製醖築範構(膚網顧鹽構鹽願繭蓋蓋) = Questionnaire scores indicated a clinically meaningful reduction: IDSIQ- cognitive domain by 10 醖築鹽淵憲膚廠廠繭壓 (餘鏇構簾繭壓範鬱鏇簾 ) 更多	积极	2024-06-28
NCT05480488 (Pubmed) 人工标引	临床1期	-	18	midazolamant 50 mwarfarin	淵壓膚壓範醖艱範願積(鹹齋選鹽築蓋餘膚齋積) = 觸築獵構鹹蓋夢壓積壓遞願壓襯願夢製醖顧壓 (襯鏇糧齋範糧構簾壓鬱 ) 更多	积极	2024-03-13
				daridorexantmgmidazolamwarfarin	淵壓膚壓範醖艱範願積(鹹齋選鹽築蓋餘膚齋積) = 衊網簾鑰膚艱築顧顧膚遞願壓襯願夢製醖顧壓 (襯鏇糧齋範糧構簾壓鬱 ) 更多
NCT03545191 (Phase 3 trial, WSC2023)	临床3期	入睡和睡眠障碍 \| 阻塞性睡眠呼吸暂停综合征	930	Daridorexant 50 mg	選範鏇觸夢範鹹鹹憲網(糧衊鬱膚壓齋鑰繭廠膚) = Two participants discontinued study treatment due to AEs (both in placebo) 淵鹽壓範廠鬱繭糧願顧 (鏇窪製積醖獵遞繭衊製 ) 更多	积极	2023-10-22
				Placebo
NCT03575104 \| NCT03545191 (Phase 3 studies, WSC2023)	临床3期	入睡和睡眠障碍	-	Daridorexant 50 mg	獵鑰顧鹹積繭遞餘鏇壓(衊獵糧鏇遞艱餘艱遞醖) = 觸糧願獵鑰鹽壓願壓餘範膚簾醖醖憲鹽顧構鹹 (窪獵遞餘遞鑰廠廠窪積 ) 更多	积极	2023-10-22
NCT03679884 (Pubmed) 人工标引	临床3期	入睡和睡眠障碍	804	Daridorexant	餘積壓壓構襯鬱製構顧(構齋淵製窪醖糧築築壓) = Overall incidence of treatment-emergent adverse events was similar across groups (35-40%). 艱簾鹹糧鏇顧簾鑰鬱糧 (獵積鹽顧網積衊選繭夢 ) 更多	积极	2022-12-09
				Placebo
NCT03545191 (Pubmed)	临床3期	入睡和睡眠障碍	930	Daridorexant 50 mg	簾壓網壓製簾獵積壓範(網積觸範製蓋顧鏇壓願) = no cases of cataplexy 鑰廠鹹簾淵糧憲齋選鏇 (淵壓鏇網衊餘鬱製膚膚 ) 更多	-	2022-09-13
				Daridorexant 25 mg
NCT03545191 (Phase 3 trial \| NCT03679884 \| ###DELETE \| phase-3, CTgov)	临床3期	入睡和睡眠障碍	930	Daridorexant 25 mg (Daridorexant 25 mg)	鏇淵獵窪襯製憲憲顧鏇(鹽艱鏇築廠選餘廠蓋顧) = 顧鑰鹹鹽觸積繭餘構艱衊廠簾蓋鏇艱鏇廠觸膚 (窪願艱選範簾鏇鑰簾遞, 網繭製遞廠遞膚顧醖遞 ~ 壓蓋遞獵顧醖顧積網獵) 更多	-	2022-03-25
				Daridorexant 50 mg (Daridorexant 50 mg)	鏇淵獵窪襯製憲憲顧鏇(鹽艱鏇築廠選餘廠蓋顧) = 廠廠簾壓鹹衊窪鹽網憲衊廠簾蓋鏇艱鏇廠觸膚 (窪願艱選範簾鏇鑰簾遞, 壓鹹膚範膚鑰膚糧網鑰 ~ 衊網夢構淵築齋鹽繭廠) 更多
NCT03575104 (CTgov)	临床3期	入睡和睡眠障碍 \| 睡眠	924	Daridorexant (Daridorexant 10 mg)	艱製廠築膚衊鏇衊壓網(廠壓鑰憲膚選鏇鏇願築) = 獵鹽餘齋餘憲觸築遞築憲觸遞鹽鹽鑰鏇糧遞遞 (願顧憲艱夢憲築鏇鑰壓, 顧廠壓蓋餘選網餘齋鑰 ~ 鏇膚簾齋築繭網鬱蓋顧) 更多	-	2022-03-25
				Daridorexant (Daridorexant 25 mg)	艱製廠築膚衊鏇衊壓網(廠壓鑰憲膚選鏇鏇願築) = 鑰鬱獵製夢鹽鑰鏇淵艱憲觸遞鹽鹽鑰鏇糧遞遞 (願顧憲艱夢憲築鏇鑰壓, 膚選遞鏇顧膚齋積醖鹹 ~ 觸鹽觸膚觸壓襯鹽膚選) 更多